Skip to main content

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Written by Customer Service on . Posted in Public Companies.

Châtillon, France, March 26, 2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

In compliance with French law, the following information are included in the 2025 URD :

  • The 2025 annual financial report;
  • The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial Code;
  • The description of the share buy-back program;
  • The statutory auditor reports;
  • The information regarding the statutory auditor fees.

These documents can be accessed on the Regulated Information section of the Company’s website at www.dbv-technologies.com. In addition, the Form 10-K is available on the SEC’s website at www.sec.gov and the 2025 URD on the AMF’s website at www.amf-france.org.

About DBV Technologies 
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children.
Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to
introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks
to modify an individual’s underlying allergy by re-educating the immune system to
become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic
people. The Company’s food allergy programs include ongoing clinical trials of the
VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and
children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company’s ordinary shares are traded on segment B
of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com        

Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.